@george_deng7 George
George posts on X about $lqda, $crvs, imo, $ocul the most. They currently have [--] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [-----] +83%
- [--] Month [-----] -7.10%
- [--] Months [------] -31%
- [--] Year [------] +461%
Mentions: [--] #
- [--] Year [--] +480%
Followers: [--] #
- [--] Week [--] +8.90%
- [--] Month [--] +15%
- [--] Months [--] +28%
- [--] Year [--] +197%
CreatorRank: [---------] #
Social Influence
Social category influence finance 23.53% stocks 12.94% technology brands 2.35% cryptocurrencies 1.18% exchanges 1.18%
Social topic influence $lqda 44.71%, $crvs 9.41%, imo 9.41%, $ocul #14, strong 3.53%, market 3.53%, $1b 3.53%, $goss #10, in the 3.53%, $omer 3.53%
Top accounts mentioned or mentioned by @octopusking77 @oneortwo1234 @zipjet @logarithmicdis @brentericson @mattnachtrab @probesreporter @dan1983p @refinedtrader1 @ascendingbio @alphahunte79332 @davydaytrades @agamemnusdev @reignmaker
Top assets mentioned Liquidia Corporation Common Stock (LQDA) Ocular Therapeutix, Inc. (OCUL) Unicycive Therapeutics, Inc. (UNCY) Sarepta Therapeutics, Inc. (SRPT) Sanofi (SNY) AbbVie Inc (ABBV) DOSE (DOSE) Super Micro Computer, Inc. Common Stock (SMCI) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Alphabet Inc Class A (GOOGL) Oracle Corporation (ORCL) United Therapeutics, Corp. (UTHR) BlackRock Inc (BLK) Goldman Sachs (GS)
Top Social Posts
Top posts by engagements in the last [--] hours
"$UNCY May get PDUFA June [--] but FDA's own target in March or April in NDA's acceptance letter next week. One example: STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF ELAMIPRETIDE NDA RESUBMISSION Press Release / August [--] 2025"
X Link 2026-01-23T16:09Z [--] followers, [---] engagements
"@oneortwo1234 @zipjet $OCUL Very likely Feb 16-20 but any day mid of next week my assumption is data base unlocked today if not already OCUL has to submit the topline data to 49th Macula Society committee for review in order to present so OCUL has to PR the topline data before submission IMO"
X Link 2026-02-05T20:29Z [--] followers, [---] engagements
"@Octopusking77 Just the opposite 95+% times companies pre-set topline data PR and CC for P2 and P3 have very strong positive data most recent one are CRVS and NKTR both PR next market day for topline data. Check them out"
X Link 2026-02-12T17:22Z [--] followers, [---] engagements
"$CRVS December [--] 2025(Friday after market close) Kymera to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December [--] [----] December [--] [----] Kymera Announces Positive Results from Phase 1b Clinical Trial of KT-621. Tuesday CRVS goes up $1B or 2B"
X Link 2026-01-17T00:07Z [--] followers, [---] engagements
"$UNCY "While the FDA considers the resubmission a complete class [--] response with a six-month user fee goal date ofFebruary [--] [----] the agency has advised the Company that its planned goal date isSeptember [--] 2025." And Approval on Sept 16"
X Link 2026-01-23T16:10Z [--] followers, [---] engagements
"$GOSS Topline data may be very likely released next Monday before the market open the trial for primary endpoint has be finished since Nov [--] [----] and it has been [--] weeks by next Monday more than enough time for the data IMO"
X Link 2026-02-04T16:27Z [--] followers, [----] engagements
"$GOSS In my view the 25K March [---] puts were sold at $.80 for $2M cash MMs have to buy the puts and hedge by shorting the stock it does not make senses to buy the put for [--] cents max if P3 fails and stock at $0.5 bullish actions IMO"
X Link 2026-02-04T17:49Z [--] followers, [---] engagements
"$OCUL "SOL-1 (Phase [--] wet AMD) superiority trial on track for topline data in the second half of February 2026." There are only [--] market days before Feb [--] for the [--] weeks topline data I guess that most likely is next Tuesday morning"
X Link 2026-02-11T19:30Z [--] followers, [----] engagements
"$GOSS The Pulmonary Hypertension Associations (PHAs) [----] International PH Conference and Scientific Sessions Dawning of a New Era will be held June [----] [----] in Dallas TX. PHA will be opening a call for Late-Breaking Abstracts beginning on Monday February 16th"
X Link 2026-02-09T14:27Z [--] followers, [----] engagements
"$OCUL 99% topline data positive 80% homerun data you do not tell street to watch me PR negative data [--] days in advance"
X Link 2026-02-13T23:09Z [--] followers, [----] engagements
"$OCUL Interesting: Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom https://business.thepilotnews.com/thepilotnews/article/marketminute-2026-2-16-sanofi-tightens-grip-on-ocular-therapeutix-with-revised-bid-as-pivotal-sol-1-trial-results-loom https://business.thepilotnews.com/thepilotnews/article/marketminute-2026-2-16-sanofi-tightens-grip-on-ocular-therapeutix-with-revised-bid-as-pivotal-sol-1-trial-results-loom"
X Link 2026-02-16T19:01Z [--] followers, [---] engagements
"$SAVA If RETHINK passes the test we may see how incompetent David Bredt lose JNJ of chance of making tens of billions with SAVA. See how much competent head of oncology can make for JNJ: JNJ is paying Pharmacyclics (PCYC) $150 million upfront for rights to co-develop and market"
X Link 2024-07-11T01:14Z [--] followers, [---] engagements
"its lead anti-cancer compound PCI-32765. AbbVie wins Pharmacyclics in $21B deal PCYC was worth $42B JNJ owns half. https://www.usatoday.com/story/money/2015/03/05/abbvie-pharmacyclics-deal/24427841/ https://seekingalpha.com/article/313249-pharmacyclics-scores-big-with-janssen-biotech-deal https://www.usatoday.com/story/money/2015/03/05/abbvie-pharmacyclics-deal/24427841/ https://seekingalpha.com/article/313249-pharmacyclics-scores-big-with-janssen-biotech-deal"
X Link 2024-07-11T01:17Z [--] followers, [--] engagements
"$SAVA Just like $GME when blood is in the water big sharks will join in for the kill my goodness shorts are too greedy now they are in danger of ruins even big guys not interest in biotech may buy in for a trade to squeeze shorts IMO"
X Link 2024-08-01T12:13Z [--] followers, [----] engagements
"$SAVA Today is a good time to buy Jan [----] call options if you believe SUMI has a very good chance RETHINK win the Jan [----] calls may catch the buyout premium IMO"
X Link 2024-08-06T15:50Z [--] followers, [---] engagements
"@LogarithmicDis @brent_ericson @MattNachtrab @probesreporter Are you out of your mind If OLE is to keep paychecks rolling it should be apposite because OLE costs lots of money"
X Link 2024-08-07T23:47Z [--] followers, [--] engagements
"$SAVA BIIB P3 Clarity AD trial with [----] patients enrolled: Finished [----] patients enrolled: early March [----] Primary endpoint trial finish: Sept [--] [----] Topline data: PR on Sept [--] [----] Data presentation: At CTAD [----] NOV [--] Time may be shorter for shorts than expected"
X Link 2024-08-15T14:21Z [--] followers, [----] engagements
"$SAVA If the new patent can extend patent protection SIMU well into 2040's it is worth GOLD because every year after [----] current patent life SUMI will make peak sales of revenue to SAVA $10B $20B. buyout price may just increase X time estimated peak sales IMO"
X Link 2024-08-20T19:46Z [--] followers, [----] engagements
"$SAVA Heavy risk model discount 10% of chance success: 10% X 25B = $2.5B $50 before data. Not include squeeze potential and buyout multiples of [--] to [--] times of estimated peak sales"
X Link 2024-09-27T17:51Z [--] followers, [---] engagements
"$SAVA BOD should authorize $50M buyback to stop the naked short selling attacks. SAVA estimates to have about $120M for [----] if RETHINK fails $120M will not save SAVA if RETINK wins SAVA wins big who care only $70M in the account SAVA can issue 2M to market at $200+ IMO"
X Link 2024-10-09T14:57Z [--] followers, [----] engagements
"$SAVA Assuming data base locked on NOV [--] the data analysis group should have the topline data now if the two primary endpoints have clean and strong efficacy P value there is 50% chance topline PR next week IMO"
X Link 2024-11-21T01:09Z [--] followers, [----] engagements
"$GLUE June 27: "In the second half of the year we expect to make a determination of our definitive recommended Phase [--] dose share updated clinical efficacy and safety results from the dose escalation arm of the trial and initiate enrollment of our Phase [--] expansion cohorts"
X Link 2024-11-27T15:08Z [--] followers, [--] engagements
"$SMCI My goodness revenue growth 65% for ($40B) FY [----] is conservative CEO says what does Charls see in his order books"
X Link 2025-02-11T22:39Z [--] followers, [---] engagements
"$LQDA No matter what the decisions from court any day approval is expected in May and fundamentally LQDA is under valued even at base case of 50% PAH and PH-ILD market shares for YUTREPIA that is $2B [--] times multiples is $4B MC IMO"
X Link 2025-02-18T15:30Z [--] followers, [---] engagements
"$LQDA Since United Therapeutics voluntarily dismissed its complaint without prejudice on Aug [--] [----] I do not think UTHR wins on cross claim 50% LQDA win both most likely outcome is both negative back to original approval in May and back to fundamentally value LQDA"
X Link 2025-02-19T16:50Z [--] followers, [---] engagements
"$LQDA Can anyone confirm LQDA's filing of estimate loss to the court on Monday"
X Link 2025-02-26T20:51Z [--] followers, [---] engagements
"$LQDA If UTHR is to buy LQDA can the deal pass the FED's antitrust laws For UTHR's own interests it is a good deal to buy out LQDA so UTHR can own PAH and PH-ILD market to 2040s and remove potential threat to IPF and PPF indications IMO"
X Link 2025-03-05T17:09Z [--] followers, [---] engagements
"And UTHR may get higher multiples of PE and peak revenue to make up more than UTHR's pay for LQDA IMO"
X Link 2025-03-05T17:11Z [--] followers, [---] engagements
"If May ACSENT data show superior efficacy and LQDA is to launch in June YUTREPIA may take majority of new PAH and PH-ILD patients UTHR may drop to low [---] range UTHR may be like JAZZ major revenue under threat that leads to very low multiples of valuation IMO"
X Link 2025-03-05T17:23Z [--] followers, [---] engagements
"@dan1983p The hate is real the pain LQDA has gone through but big institutional holders call the shots on buyout deals when the price is right IMO"
X Link 2025-03-05T18:58Z [--] followers, [---] engagements
"$LQDA UTHR's cross claim decision may come by Friday final block to approval may be removed and it is up to LQDA to decide to launch at risk or not in June IMO"
X Link 2025-03-24T18:49Z [--] followers, [----] engagements
"$LQDA On valuation compare to MDGL one drug company MC $7.3B. Analysts project that Madrigal Pharmaceuticals' Rezdiffra a treatment for metabolic dysfunction-associated steatohepatitis (MASH) could generate peak annual sales of over $3 billion"
X Link 2025-03-28T17:19Z [--] followers, [---] engagements
"$LQDA I just do not understand why the valuation gap between AKRO vs LQDA AKRO's NASH drug approval is 4+ years behind MDGL to the market and has about the same peak sales potential as YUTREPIA has AKRO $$2.8B MC LQDA $1.1B MC both are one drug company in pipeline"
X Link 2025-04-10T18:32Z [--] followers, [---] engagements
"$LQDA Only hurdle to approval is UTHR's cross claim decision now if LQDA and FDA wins the decision approval and launch are on time Judge May [--] [----] Judge Andrews denied United Therapeutics motion for a preliminary injunction to block the launch of YUTREPIA in the PH-ILD"
X Link 2025-04-11T17:55Z [--] followers, [---] engagements
"$LQDA May [--] 2024: District Court Issues Favorable Ruling andDenies United Therapeutics Request to Block YUTREPIA Launch The motion for preliminary injunction was filed in the lawsuit filed by UTHR in September [----] it has alleged YUTREPIA would infringe U.S. Patent 327"
X Link 2025-04-11T17:58Z [--] followers, [---] engagements
"$SRPT If CEO is confident of ELEVIDYS revenue estimates He should have bought back millions of stock in 50's and issue a stock offering 10+M in $100+ after recovered to pay off the $1.3B debt which is pressuring SRPT fair valuation IMO"
X Link 2025-04-22T18:29Z [--] followers, [---] engagements
"$ABEO Do we agree that With ZEVASKYN approval pending approval of UX111 strong TSHA-102 PII efficacy going into pivotal PIII the novel AIM capsid platform has been approved to be effective and safe --"
X Link 2025-05-16T18:11Z [--] followers, [---] engagements
"@RefinedTrader1 @AscendingBio $ABEO is a small company with enough cash to only run one drugs to approval so ABEO license out drugs to other companies to run PII/PIII trials to approval so ABEO can monetize asserts many years early the royalty from deals is all cash to show up in earning per share"
X Link 2025-05-18T21:14Z [--] followers, [--] engagements
"$SRPT assume distressed case of 1.4B revenue from [----] to [----] until first siRNA platform drug approval SRPT is worth [--] times 1.4B=$4.2B MC or 40-45 stock IMO"
X Link 2025-07-17T13:49Z [--] followers, [--] engagements
"$LQDA How many YUTREPIA RX is needed from June [--] launch to Aug [--] [--] months on market to consider very successful launch on Q2 earnings CC [---] 200"
X Link 2025-07-21T18:06Z [--] followers, [----] engagements
"$LQDA If CEO Roger Jeffs provides the [--] months' RX numbers and street is happy to see the launch and demand is healthy we may see squeeze to 23-25 about $2B market cap IMO"
X Link 2025-07-21T18:10Z [--] followers, [----] engagements
"@AlphaHunte79332 $LQDA Thanks for the initial DRs' very positive opinion of YUTREPIA seems street gets the message of very strong launch and shows up in the stock action we may see all [--] million shares shorted under water soon and squeeze may drive LQDA to fair price $25 before AUG [--] IMO"
X Link 2025-07-23T14:09Z [--] followers, [----] engagements
"$LQDA Expecting few bullish analysts' upgrades or comments of bullish launch in any day now. Looks all are set up to trap the shorts first by driving stock 18+ to [--] now they are ready to force them to cover fundamentally LQDA's fair value is 25-30 with strong launch IMO"
X Link 2025-07-23T14:51Z [--] followers, [---] engagements
"$LQDA should be in lock step Q by Q revenue growth with $VRNA and valuation follows too IMO"
X Link 2025-07-23T14:55Z [--] followers, [---] engagements
"$GOOGL It is Google's turn to gain 13-15% by Friday close call options point to [---] for Friday's close MSFT META AMZN and ORCL all have had more than 10% gains after earnings reports today is Google's turn to do it IMO"
X Link 2025-07-23T19:43Z [--] followers, [---] engagements
"$LQDA Yesterday's huge call option results Aug [--] call OI down 2k [----] and [--] IO up 2k. bullish [--] call writers closed out 2k IMO"
X Link 2025-07-24T13:52Z [--] followers, [---] engagements
"$LQDA I did some math for speed of VRNA Vs LQDA launch: LQDA only needs average [---] paying patients/month from OCT-DEC to make $36.6M revenue which VRNA did and was at $65 MC $5.5B. I think LQDA will have much higher net margins than VRNA UTHR net profit margin is 40%"
X Link 2025-07-24T14:52Z [--] followers, [----] engagements
"$LQDA Let's see how many Rx CEO provides on Aug earnings CC if we hear total 500-600 for June and July I think we can see the trend to beat the average [---] paying patients/month for Q4 with a big margin that beats VRNA's Q4 revenue $36.6M IMO"
X Link 2025-07-24T15:09Z [--] followers, [----] engagements
"$LQDA After close today we see short interests for July [--] anyway I am expecting margin calls going out for big shorts of 21M now because almost all 21M are underwater now. Fundamentally LQDA has $25 fair value with the strong June Rx public a squeeze may test [--] IMO"
X Link 2025-07-24T17:52Z [--] followers, [----] engagements
"$LQDA Look at the daily short volume July 1-15 huge short on July [---] and [--] we may see short interests for July [--] 23-24 million shares after close today. http://shortvolume.com/t=LQDA http://shortvolume.com/t=LQDA"
X Link 2025-07-24T18:18Z [--] followers, [---] engagements
"$LQDA Guess some funds really do believe YUTREPIA will not do well on the market according to UTHR's CEO comments well so far June YUTREPIA Rx is great and wonder how shorts can cover 22.4M shares without BIG loss now"
X Link 2025-07-24T20:14Z [--] followers, [---] engagements
"$LQDA LQDA Look at July [--] [--] [--] [--] daily volume short ratio: 70% 50% 50% and today 43% I think cover very little they are trying very hard shorting first half the day and close out by the close that lead to close at high last [--] days. https://shortvolume.com/t=LQDA https://shortvolume.com/t=LQDA"
X Link 2025-07-24T23:01Z [--] followers, [----] engagements
"$LQDA If my reasoning is right it means shorts trying to slowdown the gains but MM or some funds are buying up all the supply one day shorts may have to give up suppressing and cover"
X Link 2025-07-24T23:18Z [--] followers, [---] engagements
"$LQDA there are [--] analysts cover LQDA yesterday's average [----] revenue estimate is about $150M and today's average is $212M some analysts are quietly raising revenue estimates expecting more after earnings CC"
X Link 2025-07-25T14:01Z [--] followers, [----] engagements
"$LQDA We may see my fair price target 23-$25 by next Friday. In the face of strong YUTREPIA launch UTHR CEO may have lot to explain on weaker future revenue on July [--] earnings CC IMO"
X Link 2025-07-25T14:20Z [--] followers, [---] engagements
"@davydaytrades $LQDA My estimate is the 22.3M short interest average at price $14 and at about $133M loss on their books another $100+M loss soon IMO"
X Link 2025-07-25T14:25Z [--] followers, [---] engagements
"$LQDA May see UTHR weak guidance for rest of [----] Wednesday morning and LQDA PR for Q2 report date on Thursday should see break [--] tomorrow close and 22-23 by this Friday after Q2 CC 25-28 price target IMO"
X Link 2025-07-28T18:57Z [--] followers, [----] engagements
"$LQDA Interest comparison to SLNO with "Soleno received approximately [---] patient start forms from approximately [---] unique prescribers between March [--] [----] the date of approval of its lead product candidate VYKAT XR and June [--] 2025." and is worth $4.5B MC"
X Link 2025-07-28T18:58Z [--] followers, [----] engagements
"$LQDA Shorts or MM are working very hard to suppress LQDA yesterday was the first short volume above 50% at 53% since July [--] and still closed at year high whole last week the short volume were about 43% and LQDA gained $5 34% this week we may see $4 gain 20%"
X Link 2025-07-29T12:21Z [--] followers, [---] engagements
"$LQDA MMs are in sleep to price Aug [--] calls at $1.25 premium expecting 6.25% gain after Q2 report fundamental fair value is $25 a very big risk discount [----] times of peak sales $1B IMO"
X Link 2025-07-29T13:09Z [--] followers, [---] engagements
"$LQDA Is June [---] RX fate number No it is real and first month strong but we can debate what % market shares YUTREPIA may take 30% 40% 50% 60%"
X Link 2025-07-29T15:38Z [--] followers, [---] engagements
"$LQDA Oppenheimer says YUTREPIA takes 30% market shares of Treprostinil over $600m sales by [----] Not bad 30% market shares to start from a very bearish Oppenheimer but what is so bullish for him on UTHR if Treprostinil grows to only $2B by [----] bullshit analysis IMO"
X Link 2025-07-29T16:04Z [--] followers, [----] engagements
"$OMER Price target after a partnership signed by end of Aug $12-$15 After NARSO approval by Dec [--] PDUFA $25 in Jan [----] NARSO potential peak sales $1B for US=EU TA-TMA markets. http://investor.omeros.com/static-files/df4937d3-6ed6-4919-9b6e-368d5d1a0587 http://investor.omeros.com/static-files/df4937d3-6ed6-4919-9b6e-368d5d1a0587"
X Link 2025-07-29T19:12Z [--] followers, [--] engagements
"$LQDA Yesterday the short volume is 29% a big accumulation day by MM IMO"
X Link 2025-07-30T16:50Z [--] followers, [---] engagements
"$OCUL With actions of changing both SOL-1 and SOL-R trial SPA my guess is DMC recommended the change to speed up the approval after taking a peak at the efficacy it is a sign of extraordinary confidence of SOL-1 success to change SPA after fully enrolled IMO"
X Link 2025-08-02T14:51Z [--] followers, [---] engagements
"$LQDA $UTHR New patent [---] is issued on NOV [--] [----] it is LQDA's job to do another of court battle to invalidate it and win in the mean time UTHR may win another injunction for PH-ILD approval Am I right on this case"
X Link 2024-02-16T16:34Z [--] followers, [---] engagements
"$LQDA So far good number of holding increases: Blackrock +455840 Vangard +115367 Lm Advisors +2206443 Geode Capital + [------] Goldman Sachs +517809 and many more. Liquidia Corporation Common Stock (LQDA) Institutional Holdings Nasdaq"
X Link 2025-02-14T17:32Z [--] followers, [---] engagements
"$LQDA From yahoo yesterday post: Herbert [--] hours ago Noticing the court case filing posted yesterday it looks like Liquidia may be filing a claim for estimated calculations of lost profits arrived at by testimony from an expert in this field"
X Link 2025-02-26T15:44Z [--] followers, [---] engagements
"$LQDA This would apparently be in addition to the previous $137M judgement. I do not know if these damages would refer to United Therapeutics or the Food and Drug Administration. Liquidia Corporation (LQDA) Stock Forum & Discussion - Yahoo Finance"
X Link 2025-02-26T15:45Z [--] followers, [---] engagements
"$LQDA vs VRNA: Merck's recent acquisition of Verona Pharma for $10 billion suggests an implied peak sales target of around $3.3 billion Vs estimate peak sales for YUTREPIA around $1 billion Liquidia Corporation has expressed optimism for a market opportunity closer to $3B"
X Link 2025-07-22T14:47Z [--] followers, [---] engagements
"$LQDA $180bn of drugs coming off patent in [--] and [--] alone which is actually [--] per cent of the sectors global revenue which big pharm may be interested in LQDA in 2026"
X Link 2025-07-22T17:07Z [--] followers, [----] engagements
"$LQDA Short interets for July [------] million shares all good more fuel for short squeeze"
X Link 2025-07-24T20:03Z [--] followers, [----] engagements
"$OCUL $EYPT If OCUL is bought out the buyer should get a pediatric voucher for $100m-120M to cut the review to [--] months and may take EYPT early launch advantage away IMO"
X Link 2025-12-05T19:18Z [--] followers, [---] engagements
"$CRVS Cancelling JPM presentation news is made for partnership or buyout rumors if the deal is really in progress we may read big guys to write about it this week IMO"
X Link 2026-01-05T14:22Z [--] followers, [----] engagements
"$CRVS In a strategic planning CRVS has to raise about $100+M cash before [----] Q4 report only way to do that is to issue about 10M stocks or partnership on very strong cohort [--] efficacy data IMO"
X Link 2026-01-06T15:36Z [--] followers, [----] engagements
"@agamemnus_dev I can see a big PIIb and P3 with [--] year OLE PIIb for safety data base since FDA commissioner rules [--] P3 is enough for approval [--] years IMO"
X Link 2026-01-07T17:05Z [--] followers, [--] engagements
"@Reign_Maker Doe it makes sense to risk at .90 for Max [---] profit only stock goes to zero Anyone with a common sense may not do that IMO"
X Link 2026-02-04T18:13Z [--] followers, [--] engagements
"$PGEN compared to SLNO PGEN has lot of valuation to catch up to $4B MC IMO"
X Link 2025-08-15T18:29Z [--] followers, [---] engagements
"$OMER "On November [--] [----] the Board of Directors of the Company approved an indefinite term share repurchase program under which we may repurchase from time to time up to $100.0 million of our common stock in the open market or through privately negotiated transactions.""
X Link 2025-12-24T18:25Z [--] followers, [---] engagements
"$OMER "On November [--] [----] Omeros Corporation completed the closing of the transaction described under Item [----] below. Substantially concurrent with the closing of such transaction At the closing of the Transaction Omeros received an upfront cash payment of $240.0 million.""
X Link 2025-12-24T18:37Z [--] followers, [---] engagements
"$CRVS Why does CRVS not test the biomarkers for MOA of soquelitinib by decreasing TH2 and TH17 leading to reduce production downstream cytokine IL13 for atopic dermatitis"
X Link 2026-01-02T18:41Z [--] followers, [----] engagements
"$CRVS Something is going on with this delay PR this morning I am expecting data this week if no partnership deal in progress CRVS may issue 10M stock at $12-$15 with strong data does this delay mean some kind of deal very close"
X Link 2026-01-05T13:51Z [--] followers, [---] engagements
"$CRVS Time is huge money if CRVS follows normal trial program to approval PIIa [--] years PIIb [--] years P3 about [--] years approval [--] year that costs [--] years of patent life and [----] atopic dermatitis approval. In big pharm hands time to approval may cut to 4-5 years"
X Link 2026-01-07T16:25Z [--] followers, [---] engagements
"$CRVS On Nov [--] chat with Jeffrey Arcara on Nov. [--] for Guggenheim: CEO says "Uh yeah. We should continue to have additional data for you. So it might be a little delayed. Part of the challenge is that you have to collect the serum get all the samples in"
X Link 2026-01-07T18:44Z [--] followers, [---] engagements
"$CRVS And it takes sometimes it takes a month to get all these biomarkers analysis done. So we'll report the data but the timing we'll have to figure out" The chat is still at CRVS website"
X Link 2026-01-07T18:44Z [--] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing